Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Viruses ; 16(6)2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38932248

ABSTRACT

The emergence of the novel coronavirus SARS-CoV-2 has led to significant interest in its potential transmission between animals and humans, especially pets. This review article summarises the literature on coronavirus infections in domestic animals, emphasising epidemiology, transmission dynamics, clinical manifestations, and public health implications. This article highlights current understandings of the relationship between infections in companion animals and humans, identifies research gaps, and suggests directions for future research. Cases of disease in cats, dogs, and other domestic animals, often occurring through close contact with infected owners, are reviewed, raising concerns about possible zoonotic and reverse zoonotic transmission. Precautions and recommendations for pet owners and healthcare workers are also discussed. The scientific evidence presented in the article highlights the need for a One Health approach that considers the health of people, animals, and the environment to combat future pandemics.


Subject(s)
Animals, Wild , COVID-19 , Pets , Public Health , SARS-CoV-2 , Zoonoses , Animals , COVID-19/transmission , COVID-19/epidemiology , COVID-19/veterinary , COVID-19/virology , Pets/virology , Humans , Zoonoses/transmission , Zoonoses/epidemiology , Zoonoses/virology , Cats , Animals, Wild/virology , Dogs , Animals, Domestic/virology , One Health , Viral Zoonoses/transmission , Viral Zoonoses/epidemiology
2.
Vaccines (Basel) ; 11(12)2023 Nov 28.
Article in English | MEDLINE | ID: mdl-38140175

ABSTRACT

Creating an effective and safe vaccine is critical to fighting the coronavirus infection successfully. Several types of COVID-19 vaccines exist, including inactivated, live attenuated, recombinant, synthetic peptide, virus-like particle-based, DNA and mRNA-based, and sub-unit vaccines containing purified immunogenic viral proteins. However, the scale and speed at which COVID-19 is spreading demonstrate a global public demand for an effective prophylaxis that must be supplied more. The developed products promise a bright future for SARS-CoV-2 prevention; however, evidence of safety and immunogenicity is mandatory before any vaccine can be produced. In this paper, we report on the results of our work examining the safety, toxicity, immunizing dose choice, and immunogenicity of QazCoVac-P, a Kazakhstan-made sub-unit vaccine for COVID-19. First, we looked into the product's safety profile by assessing its pyrogenicity in vaccinated rabbit models and using the LAL (limulus amebocyte lysate) test. We examined the vaccine's acute and sub-chronic toxicity on BALB/c mice and rats. The vaccine did not cause clinically significant toxicity-related changes or symptoms in our toxicity experiments. Finally, we performed a double immunization of mice, ferrets, Syrian hamsters, and rhesus macaques (Macaca mulatta). We used ELISA to measure antibody titers with the maximum mean geometric titer of antibodies in the animals' blood sera totaling approximately 8 log2. The results of this and other studies warrant recommending the QazCoVac-P vaccine for clinical trials.

3.
Vaccines (Basel) ; 11(7)2023 Jul 04.
Article in English | MEDLINE | ID: mdl-37515015

ABSTRACT

This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for bovine tuberculosis, using an influenza vector with the NS1 mutation and expressing M. bovis protective antigens ESAT-6 and TB10.4. We vaccinated Balb/c outbred mice two times at 21 days apart. Our experimental design includes mice immunised with the candidate vaccine with or without adjuvant 15% Montanide Gel. The candidate vaccine's safety was determined by biometric analysis, and protective efficacy was assessed by bacteriological and histological experiments following a virulent M. bovis-8 strain challenge. Our data indicated that the adjuvant-free version of the vaccine ensured complete protection from the M. bovis-8 infection in mice.

4.
Microbiol Resour Announc ; 9(29)2020 Jul 16.
Article in English | MEDLINE | ID: mdl-32675181

ABSTRACT

We report the complete coding genome sequence of the influenza A/H3N8 virus, isolated from Anas querquedula in northern Kazakhstan in 2018. Phylogenetic analysis of the surface antigens of strain A/garganey/North-Kazakhstan/45/2018 showed that its hemagglutinin belonged to the Asian line, while its neuraminidase was assigned to the Eurasian group.

SELECTION OF CITATIONS
SEARCH DETAIL
...